, Inc. (NASDAQ:ARWR) on Tuesday shared interim results from two Phase 1/2a trials of ARO-INHBE and ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutics for obesity.

Preliminary results showed meaningful reductions in multiple key measures, including visceral fat, total fat, and liver fat.

What Is ARO-INHBE and ARO-ALK7 Therapy?

Unlike current GLP-1 drugs (like Wegovy or Zepbound) that primarily reduce appetite, these candidates aim to change how the body stores and burns fat by silencing specific genetic pathways.

Their primary goal is to promote weight loss while preserving lean muscle mass, a common side effect of existing weight-loss medications.

The Phase 1/2a studies of ARO-INHBE and ARO-ALK7 are ongoing, and the company expects to report and present additional results in 2026.

Arrowhead, in a press release on Tuesday, said the interim results represent the first demonstration in humans of the Activin E/ALK7 pathway, ...